Efficacy

Keytruda (Pembrolizumab) Efficacy in Gastric Cancer

Keytruda, also known by its generic name pembrolizumab, is an immunotherapy drug that has shown efficacy in the treatment of certain types of gastric cancer. It is a humanized monoclonal antibody that blocks the interaction between PD-1 (programmed death receptor-1) and its ligands, PD-L1 and PD-L2. This blockade enhances the immune response against cancer cells. Keytruda has been approved for use in patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1, as determined by an FDA-approved test, with disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy, and if appropriate, HER2/neu-targeted therapy.

The efficacy of Keytruda in gastric cancer was demonstrated in clinical trials where it showed an improvement in overall survival compared to standard chemotherapy in some patients. For instance, the KEYNOTE-059 trial evaluated Keytruda in patients with advanced gastric or GEJ adenocarcinoma. The results indicated a meaningful objective response rate in the cohort of patients whose tumors expressed PD-L1. However, it is important to note that responses may vary, and not all patients with gastric cancer will benefit from Keytruda therapy.

Jeselhy (Pimitespib) Efficacy in Gastric Cancer

Jeselhy, known generically as pimitespib, is a newer therapeutic agent that has been investigated for its efficacy in gastric cancer. Pimitespib is a heat shock protein 90 (HSP90) inhibitor, which plays a role in the stabilization and proper functioning of several proteins that are critical for the growth and survival of cancer cells. By inhibiting HSP90, pimitespib can disrupt these processes, leading to the death of cancer cells. As of the knowledge cutoff date, Jeselhy has been studied in clinical trials, but it may not yet be widely approved or available for the treatment of gastric cancer.

The available data on Jeselhy's efficacy in gastric cancer comes from early-phase clinical trials and ongoing research. These studies aim to establish the safety profile, optimal dosing, and preliminary efficacy of the drug in patients with advanced solid tumors, including gastric cancer. While the results from these studies are promising, further research is needed to fully understand the potential of Jeselhy in the treatment of gastric cancer and to obtain regulatory approvals for its use in this context.